DailyIQ
Last updatedjust now

CRL·Charles River Laboratories International, Inc.

$304.98
-5.79 (-1.86%)
After Hours
High
$333.30
Open
$319.80
Market Cap
14.55B
52W High
$312.26
Low
$300.01
P. Close
$304.98
P/E
-
52W Low
$146.19
Fwd P/E
24.40
DailyIQ Est.
$323.79
Inst. Ownership
5.3%
Short Interest
4.75%
Days to Cover
2.8
Technical Score (1D)
100
BULLISH
News Sentiment
73
BULLISH
On Oct 6, Charles River Laboratories announced the launch of Apollo Orchestrate, a new feature within its Apollo platform that integrates Autolomous’s autoloMATE digital laboratory execution system. The integration links Charles River’s Apollo and LabWare LIMS systems, bringing Autolomous’s digital LES to biopharma testing sites across North America and Europe. The move digitizes and automates laboratory workflows, enhancing quality control in GMP environments. This development supports the company’s strategic commitment to modernize lab operations and improve client‑facing transparency. The announcement highlighted the potential for more efficient and reliable laboratory execution for Charles River’s clients.
LOW TARGET
$145 -53.2%
1 analysts
MEAN TARGET
$305 -1.6%
15 analysts
HIGH TARGET
$357 +15.2%
9 analysts
PRICE RANGE
$145.00 - $357.00
SB / B / H / S / SS
6/11/6/1/1
DAILYIQ EST.
$323.79 (+4.5%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Website
Symbol
CRL
Description
Charles River Laboratories International (CRL) is a global provider of essential services for the pharmaceutical and biotechnology industries. The company operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. CRL's RMS segment supplies research models, including rodents, and related services that support preclinical drug development. The DSA segment focuses on early-stage discovery, including target identification and safety assessment, offering services like toxicology and drug metabolism analysis. Finally, the Manufacturing segment provides quality control testing for pharmaceuticals and consumer products, including specialized testing for biologics. With strategic collaborations and alliances, CRL offers a comprehensive suite of services to support the entire drug development lifecycle, from initial research to manufacturing.
Bought (1Y)
10 shares
$3K
Sold (1Y)
174,110 shares
$44.0M
Coleman GlennEVP & Chief Financial Officer
Buy10 shares2026-09-30
FOSTER JAMES C-
Option Exercise12,429 shares2026-08-25
FOSTER JAMES C-
Option Exercise21,132 shares2026-08-25
FOSTER JAMES C-
Sell33,561 shares2026-08-25
FOSTER JAMES C-
Option Exercise12,429 shares2026-08-25
54/ 100
Neutral / mixed
Overall: Neutral
✕Revenue declining year over year
✕Negative net margin
✓Positive operating cash flow
Net Margin
-3.6%
Revenue CAGR
6.9%
Current Ratio
1.29x
Debt / Equity
0.68x
Return on Equity
-4.6%
Earnings Summary
Charles River Laboratories International (CRL) is a global provider of essential services for the pharmaceutical and biotechnology industries, operating through Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments that support the entire drug development lifecycle. In the healthcare diagnostics & research sector, CRL’s diversified service mix positions it to capture demand across preclinical research and manufacturing quality control. Over the last four quarters, CRL’s earnings per share (EPS) have trended upward, with Q2 2025 EPS of $3.12 beating the $2.55 estimate, and Q2 2026 EPS of $3.02 surpassing the $2.76 forecast; revenue has remained relatively flat, hovering around $1.0 billion, with Q4 2025 revenue slightly below the $998 million estimate. The company has consistently beat analyst EPS estimates in the most recent quarters, while revenue growth has been modest and occasionally below expectations, indicating a stable but not accelerating top line. Historically, CRL has maintained a YoY revenue growth trajectory of roughly 5–7% over the past few years, with EPS growth outpacing revenue in several periods, reflecting efficient cost management and pricing power. Recent news highlights UBS and Jefferies upgrades to a buy rating and significant price target increases, underscoring analyst confidence in CRL’s earnings outlook and growth prospects.

EPS

EstBeatMiss
$1.77$2.15$2.53$2.91$3.30Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.96 - -
Q2'26$2.76$3.02+9.4%
Q1'26$1.94$2.06+6.0%
Q4'25$2.56$2.39-6.6%
Q3'25$2.34$2.43+3.9%
Q2'25$2.55$3.12+22.4%

Revenue

EstBeatMiss
$958M$979M$1000M$1.0B$1.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$968M - -
Q2'26$984M$1.0B+2.0%
Q1'26$987M$996M+0.9%
Q4'25$998M$994M-0.4%
Q3'25 - $1.0B -
Q2'25 - $1.0B -

Market Data

CRL Stock Snapshot

BULLISH100/100
$309.99+$5.01 (1.6%)
Market cap
14.55B
Day range
$300.01 – $333.30
News sentiment
73/100 · Bullish
Analyst target
$305.00 (-1.6%)
Consensus
Buy · 25 analysts
52-week range+112.0% off low · -0.7% from high
$146.19$312.26
Price $309.99 DailyIQ Est. $323.79

CRL's technical picture is constructive, with trend and momentum pointing the same direction. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Reverse DCF

What growth is priced into CRL?

RICH

At today's price, Charles River Laboratories International, Inc. needs to grow free cash flow about 24.7% a year for the next 10 years to justify its valuation at a 9.90% cost of capital. Over its actual history it has compounded free cash flow at 10.1% a year, so the market is asking for 14.7 percentage points above its own delivered rate. On that basis CRL looks priced above what its own growth record supports.

Implied FCF growth
24.7%
Historical FCF CAGR
10.1%
Growth gap
+14.7 pts
Verdict
RICH
Discount rate (WACC)
9.90%
Beta
1.09

Behaviour On Record

What CRL's own history says about today's numbers

Realized volatility (21d)
41.3% 80th pct
Below its peak
-32.2%
vs 200-day average
+48.0%
Up days (1y)
54%

Charles River Laboratories International, Inc. is currently running 41.3% annualised volatility over the last 21 sessions. Measured against CRL's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 29.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CRL is trading -32.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -25.2%, and the deepest was -49.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +48.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 100th percentile — a wider gap than this stock usually carries. Over the past year CRL closed higher on 54% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, CRL finished the month higher 8 of 13 times, with a median return of +3.4% and an average of +0.1%. Its strongest month historically has been July at +6.8% on average, its weakest April at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CRL has opened more than 2% away from the prior close in 167 of 3,267 sessions (5.1% of the time), with the largest gaps running +7.1% and -13.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, CRL moved an average of 2.2% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.4% and a largest of +3.9%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against CRL's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CRL's sector?

Charles River Laboratories International, Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for CRL?

CallsPuts

For Charles River Laboratories International, Inc.'s nearest expiry (2026-10-16, 10 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.63), with at-the-money implied volatility around 53.2%. The options market is pricing roughly a ±8.4% move by that expiry — a range of about $271.13–$320.79.

Put/call ratio (2026-10-16)
0.63
ATM implied volatility
53.2%
Total open interest
3,023
Expected move by 2026-10-16
±8.4% ($271.13–$320.79)

Analyst Rating Changes

Are analysts turning bullish or bearish on CRL?

Jefferies most recently reiterated its rating on Charles River Laboratories International, Inc. to Buy on Sep 28, 2026 with a price target of $340 (from $305). Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.

Latest action
Jefferies — Buy
90-day upgrades
1
90-day downgrades
1
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 28, 2026JefferiesMaintainedBuy$305 → $340
Sep 25, 2026Deutsche BankMaintainedBuy$300 → $320
Sep 25, 2026TD CowenMaintainedBuy$300 → $325
Sep 25, 2026Evercore ISI GroupMaintainedOutperform$320 → $330
Sep 25, 2026RBC CapitalMaintainedOutperform$282 → $322
Sep 25, 2026BarclaysMaintainedOverweight$300 → $330
Sep 25, 2026MizuhoMaintainedNeutral$264 → $295
Sep 25, 2026BairdMaintainedOutperform$291 → $334
Sep 11, 2026Evercore ISI GroupMaintainedOutperform$300 → $320
Aug 10, 2026TD CowenMaintainedBuy$235 → $300
Aug 7, 2026Morgan StanleyMaintainedOverweight$260 → $300
Aug 6, 2026RBC CapitalMaintainedOutperform$215 → $282

CRL Competitive Positioning

Charles River Laboratories International, Inc. (CRL) is tracked alongside these names in Diagnostics & Research on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

73/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Charles River Laboratories announced the launch of Apollo Orchestrate, a new feature within its Apollo platform that integrates Autolomous’s autoloMATE digital laboratory execution system. The integration digitizes and automates laboratory workflows across North American and European sites, enhancing quality control in GMP environments. The move supports the company’s strategic commitment to modernize lab operations and improve client-facing transparency.
What did this article say?
Charles River Laboratories International (CRL) announced a partnership with Autolomous to launch Apollo, a digital platform aimed at automating laboratory execution. The collaboration focuses on integrating Autolomous’s autonomous technology with CRL’s laboratory services to enhance data transparency and operational efficiency. By digitizing workflows, the joint effort seeks to improve client experience and reduce manual errors. The move underscores CRL’s commitment to expanding its digital and automation capabilities in the life‑science sector.
What did this article say?
Charles River Laboratories lifted its fair‑value estimate to $305 following its investor and analyst days, with multiple research houses raising price targets into a $260–$330 range. The revisions reflect a more optimistic view of the company’s long‑range plan and margin goals. The upward re‑pricing signals a positive market consensus and may support a higher valuation for the stock.
What did this article say?
Analysts updated their consensus price target for Charles River Laboratories International (CRL) upward by 11.46%, setting it at $307.39. The revision reflects expectations of stronger earnings and continued growth in the contract research services sector. The new target suggests that market participants view CRL’s business model favorably and anticipate solid performance in the coming quarters. This adjustment is likely to influence investor perception and could support a modest rally in the stock price. The update underscores confidence in CRL’s ability to generate revenue growth amid a competitive landscape.
What did this article say?
The press release highlighted a projected rise in the global animal model market to $3.6 billion by 2032, driven by CRISPR, AI, and humanized models. Charles River Laboratories (CRL) is positioned to benefit from increased demand for animal models in drug and vaccine research. The growth is supported by rising biomedical research investment and a higher prevalence of chronic diseases. CRL’s role as a leading provider of animal models suggests a positive impact on its business prospects. The report underscores the company’s strategic alignment with emerging technologies in the life‑science sector.
What did this article say?
UBS upgraded Charles River Laboratories International from neutral to buy and lifted its price target from $175 to $357. The upgrade reflects confidence in CRL’s growth prospects and earnings outlook. The significant target increase signals a bullish view on the company’s valuation and future performance. This move may influence investor sentiment and trading activity in the near term.
What did this article say?
Charles River (CRL) delivered an average annual return of 16.72% over the past 15 years, outperforming the market by 3.32% on an annualized basis. The company’s market capitalization stands at $15.15 billion. This historical performance highlights CRL’s strong investment track record and resilience in a volatile market environment. The data underscores the firm’s ability to generate consistent returns for shareholders. No recent operational or strategic changes were disclosed in the report.
What did this article say?
On September 29, 2026, Charles River Laboratories entered a Statement of Work with NorthStrive Biosciences to perform analytical characterization of the EL-22 and EL-32 engineered probiotic programs. The collaboration focuses on measuring plasmid copy numbers and other DNA metrics to support IND‑enabling development. The partnership enhances NorthStrive’s manufacturing and characterization capabilities, positioning the company closer to regulatory milestones. Charles River’s expertise is expected to streamline data generation and reduce time to market for the probiotic candidates.

Technical Analysis

Real-time indicators across multiple timeframes

100
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
3 tracked managers · $569.02M combined position · 2 adding, 1 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Geode Capital Management, LLC▲ Buy1,305,7382.78%$295.60M2026-08-12
Neuberger Berman Group LLC▼ Sell862,7041.84%$195.63M2026-08-13
Marshall Wace, LLP▲ Buy342,9950.73%$77.79M2026-08-13
Q2 2026 flow:193.4K sh bought ($43.86M)11.7K sh sold ($2.65M)net +181.7K sh (+$41.21M)
Congressional Trading Activity
5 disclosed trades · ~$113.5K est. traded value · 3 buys, 2 sells
MemberChamberStateTypeAmountTradedFiled
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-05-082025-06-22
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-04-082025-05-08
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-01-152025-02-12